Hiking the Appalachian Trail for Gillen
…for melanoma research, please visit Tim’s event page HERE. Checks may be made out to AIM at Melanoma Foundation, Memo: Gillen’s…
Hiking the Appalachian Trail for Gillen
…for melanoma research, please visit Tim’s event page HERE. Checks may be made out to AIM at Melanoma Foundation, Memo: Gillen’s…
,
,
President’s Letter | September 2021
From the Desk of Samantha Guild As I reviewed the articles for this month’s newsletter, I thought about the fact…
,
What Makes AIM’s IMTBC Even More Valuable
AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
,
Ways to Give: What Is Payroll Giving?
…AIM at Melanoma’s mission, but also becoming part of our community of dedicated individuals and companies working towards a world…
,
RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…
,
Sketching Her Way Through Metastatic Melanoma
By Alicia Rowell, Vice President, AIM at Melanoma Nearly every melanoma patient or survivor that AIM has met has a coping…
,
AIM’s Steps Against Melanoma Walks Go Virtual
…free for all virtual walks, and all registered melanoma survivors will receive a complimentary Melanoma Warrior t-shirt. Thank you to…
In Plain English: The Role of Dermatopathologists in Diagnosing Melanoma Patients
…example, they will decide if it is melanoma or not. When your tissue arrives at the lab, a technician prepares…
,
Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma
…IIC melanoma after a median follow up of 27.4 months (range, 14.0-39.4). Georgina V. Long, MD, PhD, FRACP, of the…
,
Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma
…estimated 99,780 new cases diagnosed and 7,650 deaths due to melanoma in 2022. A steep drop in melanoma deaths from…
,
Recent Posts
Mar. 26, 2026
Wade Watson, Stage III Melanoma Survivor: A Marathon, Not a Sprint
Mar. 03, 2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026